High Serum Levels of Soluble IL-2 Receptor, Cytokines, and C Reactive Protein Correlate with Impairment of T Cell Response in Patients with Advanced Epithelial Ovarian Cancer

By Maccio A.   Lai P.   Santona M.C.   Pagliara L.   Melis G.B.   Mantovani G.  

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 248-252

Elsevier

Access to resources Recommend Favorite

The Prognostic Implication of Ascites in Advanced-Stage Ovarian Cancer

By Puls L.E.   Duniho T.   Hunter IV J.E.   Kryscio R.   Blackhurst D.   Gallion H.  

Gynecologic Oncology, Vol. 61, Iss. 1, 1996-04 ,pp. : 109-112

Academic Press

Access to resources Recommend Favorite

Cellular Glutathione Content, in Vitro Chemoresponse, and the Effect of BSO Modulation in Samples Derived from Patients with Advanced Ovarian Cancer

By Lewandowicz G.M.   Britt P.   Elgie A.W.   Williamson C.J.   Coley H.M.   Hall A.G.   Sargent J.M.  

Gynecologic Oncology, Vol. 85, Iss. 2, 2002-05 ,pp. : 298-304

Academic Press

Access to resources Recommend Favorite

Effect of tumor suppressor gene cyclindependent kinase inhibitor 2A wildtype and A148T mutant on the cell cycle of human ovarian cancer cells

By            

Oncology Letters, Vol. 7, Iss. 4, 2014-01 ,pp. : 1229-1232

Spandidos Publications

Access to resources Recommend Favorite

Goserelin can inhibit ovarian cancer proliferation and simultaneously protect ovarian function from cisplatin: an in vitro and in vivo study

By Zhang Ying   Ding Jing Xin   Tao Xiang   Lu Zhi Ying   Wang Jia Jia   Feng Wei Wei   Hua Ke Qin  

Journal of Chemotherapy, Vol. 25, Iss. 2, 2013-04 ,pp. : 96-103

Maney Publishing

Access to resources Recommend Favorite